Anthera Pharmaceuticals (ANTH)
(Delayed Data from OTC)
$NA USD
0 (0.00%)
Updated Aug 21, 2024 01:47 PM ET
NA Value
NA Growth NA Momentum NA VGMCompany Summary
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company's clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California.
Company Summary
General Information
Anthera Pharmaceuticals, Inc
25801 INDUSTRIAL BOULEVARD SUITE B
HAYWARD, CA 94545
Phone: 510-856-5600
Fax: 510-856-5597
Email: NA
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | NA |
EPS Information
Current Quarter EPS Consensus Estimate | NA |
Current Year EPS Consensus Estimate | NA |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | NA |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | NA |
52 Week High | 0.01 |
52 Week Low | 0.00 |
Beta | NA |
20 Day Moving Average | 0.00 |
Target Price Consensus | 0.00 |
4 Week | NA |
12 Week | NA |
YTD | NA |
4 Week | NA |
12 Week | NA |
YTD | NA |
Shares Outstanding (millions) | NA |
Market Capitalization (millions) | NA |
Short Ratio | NA |
Last Split Date | 5/1/2017 |
Dividend Yield | NA% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $NA |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | NA |
vs. Previous Quarter | NA |
vs. Previous Year | NA% |
vs. Previous Quarter | NA% |
Price/Book | NA |
Price/Cash Flow | NA |
Price / Sales | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |